VRTX
Vertex Pharmaceuticals Incorporated$476.29+0.40 (+0.08%)Prev Close$476.31·MCap$126.50B·P/E28.13·Vol709.4K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
58
$146.95M
◆
Net Activity
Net Seller
$146.95M
●
Active Insiders
13
last 12 mo
Over the past 12 months, insider activity at Vertex Pharmaceuticals Incorporated (VRTX) has been exclusively selling, with 0 insider purchases totaling $0.00 and 58 insider sales totaling $146.95M. The most recent insider transaction was by McKechnie Duncan (officer: EVP, Chief Commercial Officer), who sold $799.8K worth of shares on Jul 7, 2026. Vertex Pharmaceuticals Incorporated operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $126.50B.
VRTX Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | McKechnie Duncan | officer: EVP, Chief Commercial Officer | Sell | 1,541 | $519.00 | $799.8K | 11,001 |
| Jul 7, 2026 | Tatsis Ourania | officer: EVP, Chief Reg. & Quality Off. | Sell | 1,500 | $524.99 | $787.5K | 45,321 |
| Jul 6, 2026 | Liu Joy | officer: EVP and Chief Legal Officer | Sell | 828 | $502.71 | $416.2K | 19,131 |
| Jun 30, 2026 | Bozic Carmen | officer: EVP and CMO | Sell | 596 | $482.50 | $287.6K | 15,337 |
| Jun 23, 2026 | Bozic Carmen | officer: EVP and CMO | Sell | 1,020 | $462.17 | $471.4K | 15,933 |
| Jun 17, 2026 | Bozic Carmen | officer: EVP and CMO | Sell | 4,062 | $450.00 | $1.83M | 16,953 |
| Jun 9, 2026 | Bozic Carmen | officer: EVP and CMO | Sell | 1,745 | $450.00 | $785.3K | 21,015 |
| Jun 2, 2026 | Bozic Carmen | officer: EVP and CMO | Sell | 1,974 | $450.00 | $888.3K | 22,760 |
| May 19, 2026 | Bunnage Mark E. | officer: EVP, Chief Scientific Officer | Sell | 33 | $453.45 | $15.0K | 7,284 |
| May 19, 2026 | Bozic Carmen | officer: EVP and CMO | Sell | 1,354 | $453.45 | $614.0K | 24,734 |
| May 14, 2026 | Bozic Carmen | officer: EVP and CMO | Sell | 6,988 | $450.00 | $3.14M | 26,088 |
| May 5, 2026 | Bhatia Sangeeta N. | director | Sell | 318 | $423.73 | $134.7K | 4,924 |
| May 5, 2026 | Liu Joy | officer: EVP and Chief Legal Officer | Sell | 1,104 | $425.02 | $469.2K | 20,729 |
| Apr 3, 2026 | Liu Joy | officer: EVP and Chief Legal Officer | Sell | 978 | $449.17 | $439.3K | 21,833 |
| Mar 31, 2026 | Bozic Carmen | officer: EVP and CMO | Sell | 2,329 | $450.95 | $1.05M | 33,076 |
| Mar 17, 2026 | Bozic Carmen | officer: EVP and CMO | Sell | 2,329 | $481.79 | $1.12M | 35,405 |
| Mar 13, 2026 | McKechnie Duncan | officer: EVP, Chief Commercial Officer | Sell | 2,633 | $498.42 | $1.31M | 12,489 |
| Mar 6, 2026 | McKechnie Duncan | officer: EVP, Chief Commercial Officer | Sell | 2,437 | $475.30 | $1.16M | 15,122 |
| Mar 3, 2026 | Bozic Carmen | officer: EVP and CMO | Sell | 2,329 | $480.31 | $1.12M | 37,734 |
| Mar 3, 2026 | Kewalramani Reshma | director, officer: CEO & President | Sell | 40,000 | $493.47 | $19.74M | 137,878 |
| Mar 2, 2026 | Ambrose Kristen | officer: SVP & Chief Accounting Officer | Sell | 357 | $483.36 | $172.6K | 6,624 |
| Feb 26, 2026 | Ambrose Kristen | officer: SVP & Chief Accounting Officer | Sell | 223 | $486.35 | $108.5K | 6,981 |
| Feb 26, 2026 | Atkinson Edward Morrow III | officer: EVP, Chief Technical Ops. Off. | Sell | 668 | $486.35 | $324.9K | 18,432 |
| Feb 26, 2026 | Biller Jonathan | officer: EVP and Chief Legal Officer | Sell | 945 | $486.35 | $459.6K | 13,659 |
| Feb 26, 2026 | Bunnage Mark E. | officer: EVP, Chief Scientific Officer | Sell | 620 | $486.35 | $301.5K | 7,284 |
| Feb 26, 2026 | McKechnie Duncan | officer: EVP, Chief Commercial Officer | Sell | 4,910 | $487.65 | $2.39M | 19,969 |
| Feb 26, 2026 | Sachdev Amit | officer: EVP Chief Patient & Ext Af Off | Sell | 1,846 | $486.35 | $897.8K | 55,570 |
| Feb 26, 2026 | Tatsis Ourania | officer: EVP, Chief Reg. & Quality Off. | Sell | 260 | $486.35 | $126.5K | 46,763 |
| Feb 19, 2026 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | Sell | 4,378 | $484.52 | $2.12M | 0 |
| Feb 19, 2026 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Sell | 58,613 | $468.83 | $27.48M | 0 |
| Feb 17, 2026 | Ambrose Kristen | SVP & Chief Accounting Officer | Sell | 2,793 | $484.63 | $1.35M | 0 |
| Feb 17, 2026 | Biller Jonathan | EVP and Chief Legal Officer | Sell | 5,225 | $484.06 | $2.53M | 0 |
| Feb 17, 2026 | Bozic Carmen | EVP and CMO | Sell | 1,912 | $483.75 | $924.9K | 0 |
| Feb 17, 2026 | Bunnage Mark E. | EVP, Chief Scientific Officer | Sell | 4,729 | $484.18 | $2.29M | 0 |
| Feb 17, 2026 | Kewalramani Reshma | CEO & President | Sell | 6,554 | $483.75 | $3.17M | 0 |
| Feb 17, 2026 | LEIDEN JEFFREY M | Executive Chairman | Sell | 2,964 | $483.75 | $1.43M | 0 |
| Feb 17, 2026 | McKechnie Duncan | EVP, Chief Commercial Officer | Sell | 1,148 | $483.75 | $555.3K | 0 |
| Feb 17, 2026 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Sell | 2,140 | $483.75 | $1.04M | 0 |
| Feb 17, 2026 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Sell | 977 | $483.52 | $472.4K | 0 |
| Feb 17, 2026 | WAGNER CHARLES F JR | EVP, CO & FO | Sell | 2,294 | $483.75 | $1.11M | 0 |
| Feb 13, 2026 | Ambrose Kristen | SVP & Chief Accounting Officer | Sell | 1,393 | $487.76 | $679.5K | 0 |
| Feb 13, 2026 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | Sell | 1,903 | $487.76 | $928.2K | 0 |
| Feb 13, 2026 | Bhatia Sangeeta N. | Director | Sell | 266 | $500.00 | $133.0K | 0 |
| Feb 13, 2026 | Biller Jonathan | EVP and Chief Legal Officer | Sell | 3,981 | $490.55 | $1.95M | 0 |
| Feb 13, 2026 | Kewalramani Reshma | CEO & President | Sell | 13,041 | $487.76 | $6.36M | 0 |
| Feb 13, 2026 | McKechnie Duncan | EVP, Chief Commercial Officer | Sell | 2,283 | $487.76 | $1.11M | 0 |
| Feb 13, 2026 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Sell | 3,548 | $487.76 | $1.73M | 0 |
| Feb 13, 2026 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Sell | 5,304 | $491.22 | $2.61M | 0 |
| Feb 13, 2026 | WAGNER CHARLES F JR | EVP, CO & FO | Sell | 4,565 | $487.76 | $2.23M | 0 |
| Feb 12, 2026 | Ambrose Kristen | officer: SVP & Chief Accounting Officer | Sell | 1,376 | $460.43 | $633.6K | 10,127 |
Showing 1–50 of 271
1 / 6
...
VRTX Insider Buying Activity
The following table shows recent insider purchases of Vertex Pharmaceuticals Incorporated (VRTX) stock reported via SEC Form 4 filings.
No insider buying activity found for VRTX in the last 12 months.
VRTX Insider Selling Activity
The following table shows recent insider sales of Vertex Pharmaceuticals Incorporated (VRTX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | McKechnie Duncan | officer: EVP, Chief Commercial Officer | Sell | 1,541 | $519.00 | $799.8K | 11,001 |
| Jul 7, 2026 | Tatsis Ourania | officer: EVP, Chief Reg. & Quality Off. | Sell | 1,500 | $524.99 | $787.5K | 45,321 |
| Jul 6, 2026 | Liu Joy | officer: EVP and Chief Legal Officer | Sell | 828 | $502.71 | $416.2K | 19,131 |
| Jun 30, 2026 | Bozic Carmen | officer: EVP and CMO | Sell | 596 | $482.50 | $287.6K | 15,337 |
| Jun 23, 2026 | Bozic Carmen | officer: EVP and CMO | Sell | 1,020 | $462.17 | $471.4K | 15,933 |
| Jun 17, 2026 | Bozic Carmen | officer: EVP and CMO | Sell | 4,062 | $450.00 | $1.83M | 16,953 |
| Jun 9, 2026 | Bozic Carmen | officer: EVP and CMO | Sell | 1,745 | $450.00 | $785.3K | 21,015 |
| Jun 2, 2026 | Bozic Carmen | officer: EVP and CMO | Sell | 1,974 | $450.00 | $888.3K | 22,760 |
| May 19, 2026 | Bunnage Mark E. | officer: EVP, Chief Scientific Officer | Sell | 33 | $453.45 | $15.0K | 7,284 |
| May 19, 2026 | Bozic Carmen | officer: EVP and CMO | Sell | 1,354 | $453.45 | $614.0K | 24,734 |
| May 14, 2026 | Bozic Carmen | officer: EVP and CMO | Sell | 6,988 | $450.00 | $3.14M | 26,088 |
| May 5, 2026 | Bhatia Sangeeta N. | director | Sell | 318 | $423.73 | $134.7K | 4,924 |
| May 5, 2026 | Liu Joy | officer: EVP and Chief Legal Officer | Sell | 1,104 | $425.02 | $469.2K | 20,729 |
| Apr 3, 2026 | Liu Joy | officer: EVP and Chief Legal Officer | Sell | 978 | $449.17 | $439.3K | 21,833 |
| Mar 31, 2026 | Bozic Carmen | officer: EVP and CMO | Sell | 2,329 | $450.95 | $1.05M | 33,076 |
| Mar 17, 2026 | Bozic Carmen | officer: EVP and CMO | Sell | 2,329 | $481.79 | $1.12M | 35,405 |
| Mar 13, 2026 | McKechnie Duncan | officer: EVP, Chief Commercial Officer | Sell | 2,633 | $498.42 | $1.31M | 12,489 |
| Mar 6, 2026 | McKechnie Duncan | officer: EVP, Chief Commercial Officer | Sell | 2,437 | $475.30 | $1.16M | 15,122 |
| Mar 3, 2026 | Bozic Carmen | officer: EVP and CMO | Sell | 2,329 | $480.31 | $1.12M | 37,734 |
| Mar 3, 2026 | Kewalramani Reshma | director, officer: CEO & President | Sell | 40,000 | $493.47 | $19.74M | 137,878 |
| Mar 2, 2026 | Ambrose Kristen | officer: SVP & Chief Accounting Officer | Sell | 357 | $483.36 | $172.6K | 6,624 |
| Feb 26, 2026 | Ambrose Kristen | officer: SVP & Chief Accounting Officer | Sell | 223 | $486.35 | $108.5K | 6,981 |
| Feb 26, 2026 | Atkinson Edward Morrow III | officer: EVP, Chief Technical Ops. Off. | Sell | 668 | $486.35 | $324.9K | 18,432 |
| Feb 26, 2026 | Biller Jonathan | officer: EVP and Chief Legal Officer | Sell | 945 | $486.35 | $459.6K | 13,659 |
| Feb 26, 2026 | Bunnage Mark E. | officer: EVP, Chief Scientific Officer | Sell | 620 | $486.35 | $301.5K | 7,284 |
| Feb 26, 2026 | McKechnie Duncan | officer: EVP, Chief Commercial Officer | Sell | 4,910 | $487.65 | $2.39M | 19,969 |
| Feb 26, 2026 | Sachdev Amit | officer: EVP Chief Patient & Ext Af Off | Sell | 1,846 | $486.35 | $897.8K | 55,570 |
| Feb 26, 2026 | Tatsis Ourania | officer: EVP, Chief Reg. & Quality Off. | Sell | 260 | $486.35 | $126.5K | 46,763 |
| Feb 19, 2026 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | Sell | 4,378 | $484.52 | $2.12M | 0 |
| Feb 19, 2026 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Sell | 58,613 | $468.83 | $27.48M | 0 |
| Feb 17, 2026 | Ambrose Kristen | SVP & Chief Accounting Officer | Sell | 2,793 | $484.63 | $1.35M | 0 |
| Feb 17, 2026 | Biller Jonathan | EVP and Chief Legal Officer | Sell | 5,225 | $484.06 | $2.53M | 0 |
| Feb 17, 2026 | Bozic Carmen | EVP and CMO | Sell | 1,912 | $483.75 | $924.9K | 0 |
| Feb 17, 2026 | Bunnage Mark E. | EVP, Chief Scientific Officer | Sell | 4,729 | $484.18 | $2.29M | 0 |
| Feb 17, 2026 | Kewalramani Reshma | CEO & President | Sell | 6,554 | $483.75 | $3.17M | 0 |
| Feb 17, 2026 | LEIDEN JEFFREY M | Executive Chairman | Sell | 2,964 | $483.75 | $1.43M | 0 |
| Feb 17, 2026 | McKechnie Duncan | EVP, Chief Commercial Officer | Sell | 1,148 | $483.75 | $555.3K | 0 |
| Feb 17, 2026 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Sell | 2,140 | $483.75 | $1.04M | 0 |
| Feb 17, 2026 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Sell | 977 | $483.52 | $472.4K | 0 |
| Feb 17, 2026 | WAGNER CHARLES F JR | EVP, CO & FO | Sell | 2,294 | $483.75 | $1.11M | 0 |
| Feb 13, 2026 | Ambrose Kristen | SVP & Chief Accounting Officer | Sell | 1,393 | $487.76 | $679.5K | 0 |
| Feb 13, 2026 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | Sell | 1,903 | $487.76 | $928.2K | 0 |
| Feb 13, 2026 | Bhatia Sangeeta N. | Director | Sell | 266 | $500.00 | $133.0K | 0 |
| Feb 13, 2026 | Biller Jonathan | EVP and Chief Legal Officer | Sell | 3,981 | $490.55 | $1.95M | 0 |
| Feb 13, 2026 | Kewalramani Reshma | CEO & President | Sell | 13,041 | $487.76 | $6.36M | 0 |
| Feb 13, 2026 | McKechnie Duncan | EVP, Chief Commercial Officer | Sell | 2,283 | $487.76 | $1.11M | 0 |
| Feb 13, 2026 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Sell | 3,548 | $487.76 | $1.73M | 0 |
| Feb 13, 2026 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Sell | 5,304 | $491.22 | $2.61M | 0 |
| Feb 13, 2026 | WAGNER CHARLES F JR | EVP, CO & FO | Sell | 4,565 | $487.76 | $2.23M | 0 |
| Feb 12, 2026 | Ambrose Kristen | officer: SVP & Chief Accounting Officer | Sell | 1,376 | $460.43 | $633.6K | 10,127 |
VRTX Insiders
Kewalramani Reshma
director, officer: CEO & President
Bought $1.96MSold $91.54M
18 tradesLast: Mar 3, 2026
Atkinson Edward Morrow III
officer: EVP, Chief Technical Ops. Off.
Sold $10.35M
10 tradesLast: Feb 26, 2026
Similar Stocks to VRTX
REGN
Regeneron Pharmaceuticals, Inc.
$662.73+1.01%
$68.29B
ALNY
Alnylam Pharmaceuticals, Inc.
$275.93-1.72%
$43.19B
RVMD
Revolution Medicines, Inc.
$185.71+0.42%
$40.34B
MRNA
Moderna, Inc.
$68.11+1.00%
$27.09B
INSM
Insmed Incorporated
$109.25-0.67%
$25.06B
INCY
Incyte Corporation
$114.43-0.30%
$23.32B
UTHR
United Therapeutics Corporation
$530.63+0.75%
$23.22B
NBIX
Neurocrine Biosciences, Inc.
$170.83-0.71%
$17.81B